Fig. 2: Fasting enhances GR and PR chromatin binding and decreases enhancer activity at JUN sites. | Nature

Fig. 2: Fasting enhances GR and PR chromatin binding and decreases enhancer activity at JUN sites.

From: Fasting boosts breast cancer therapy efficacy via glucocorticoid activation

Fig. 2: Fasting enhances GR and PR chromatin binding and decreases enhancer activity at JUN sites.The alternative text for this image may have been generated using AI.

a, Representative immunohistochemistry staining for ERα, GR and PR in MCF7 xenografted tumours in the different treatment arms (n = 4). n represents number of mice per treatment group. Scale bars, 100 μm. b, Heat map depicting ChIP–seq signal for GR and PR in xenografts for all treatment arms. Regions altered in response to fasting in TMX-treated mice are shown. c, Average ChIP–seq signal for GR and PR for all conditions at sites that are enriched in the TMX plus fasting condition, with data centred on the peak, within a ±2-kb window. Data are mean ± s.e.m. d, ChIP–seq heat map signal for JUN in xenografts for all treatment conditions at H3K27ac regions that are differentially enriched in TMX and TMX plus fasting. e, Average JUN ChIP–seq signal for all conditions at H3K27ac regions that are enriched in TMX (left) and TMX plus fasting (right) conditions. Data are centred at the JUN peak, with a ± 2-kb window around the peak. Data are mean ± s.e.m. f, Schematic representation of blood collection schedule. Blood was collected from MCF7 xenografted mice before initiating the first cycle of fasting for all treatment conditions. Blood collection was repeated after the fourth cycle of fasting, when the mice were euthanized. Adapted from Servier Medical Art (https://smart.servier.com), CC BY 4.0. g, Corticosterone and progesterone levels in blood of mice before and after four cycles of TMX plus fasting (n = 9). n represents number of mice per treatment group. Data were analysed by two-tailed Wilcoxon signed rank test. h, Schematic representation of serum collection from patients with breast cancer who were being treated with endocrine therapy, before and after five days of FMD. Adapted from Servier Medical Art (https://smart.servier.com), CC BY 4.0. i, Cortisol and progesterone concentrations in serum of patients with ERα+ breast cancer, as described in h. Data were analysed by two-tailed Student’s paired t-test. j, Cortisol concentrations in serum of patients with ERα+ breast cancer before and after five days of FMD. Data were analysed by two-tailed Student’s paired t-test.

Source data

Back to article page